Madam Speaker, as a point of clarification, the member has said that he has heard members of the House denounce a national pharmacare system. I want to have a better understanding of how he came to that conclusion, because that is not at all what I have heard today.
What I have heard today is an all-party commitment for our health committee to examine this issue and to inform the government of its examination. I have heard about the remarkable amount of work and the number of witnesses the committee has called. In fact, it was the health committee that asked the parliamentary budget officer to report back to it.
It seems to me that the health committee has identified this as an issue worthy of examination, that it has taken extraordinary steps to hear from witnesses and to gather information so it might complete a report.
What the member has heard from our government is a tireless effort from the outset of our mandate to reduce the costs and to increase the accessibility of pharmaceuticals for all of our citizens, and of our work with the provinces and territories to try to come to better agreements and to bring efficiency, affordability, and accessibility to the pharmacare system.
The member said that he heard somebody in this room denouncing this notion. Frankly, I have not heard that. Perhaps the member could clarify his remark.